Novartis Earns Unanimous Recommendation for FDA Approval of CAR-T Cell Therapy

We may not have to wait much longer for the first FDA-approved CAR-T cell therapy. The Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) recently recommended Novartis’ CTL019 CAR-T cell therapy for FDA approval by unanimous decision, a major step forward for the groundbreaking biologic. CTL019, indicated for pediatric and young adult r/r B…